BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 29730257)

  • 1. Regulation of the Antioxidant Response by MyoD Transcriptional Coactivator in Castration-resistant Prostate Cancer Cells.
    Zhang S; Li LH; Qiao HM; Yang X; Chen L; Luo XH
    Urology; 2019 Jan; 123():296.e9-296.e18. PubMed ID: 29730257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nrf1 and Nrf2 transcription factors regulate androgen receptor transactivation in prostate cancer cells.
    Schultz MA; Hagan SS; Datta A; Zhang Y; Freeman ML; Sikka SC; Abdel-Mageed AB; Mondal D
    PLoS One; 2014; 9(1):e87204. PubMed ID: 24466341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer.
    Ren S; Liu Y; Xu W; Sun Y; Lu J; Wang F; Wei M; Shen J; Hou J; Gao X; Xu C; Huang J; Zhao Y; Sun Y
    J Urol; 2013 Dec; 190(6):2278-87. PubMed ID: 23845456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
    Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
    Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression.
    Shiota M; Yokomizo A; Tada Y; Inokuchi J; Kashiwagi E; Masubuchi D; Eto M; Uchiumi T; Naito S
    Oncogene; 2010 Jan; 29(2):237-50. PubMed ID: 19802001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dihydrotestosterone enhances castration-resistant prostate cancer cell proliferation through STAT5 activation via glucocorticoid receptor pathway.
    Song C; Kim Y; Min GE; Ahn H
    Prostate; 2014 Sep; 74(12):1240-8. PubMed ID: 25043756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
    Ishikura N; Kawata H; Nishimoto A; Nakamura R; Tsunenari T; Watanabe M; Tachibana K; Shiraishi T; Yoshino H; Honma A; Emura T; Ohta M; Nakagawa T; Houjo T; Corey E; Vessella RL; Aoki Y; Sato H
    Int J Oncol; 2015 Apr; 46(4):1560-72. PubMed ID: 25634071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nelfinavir inhibits regulated intramembrane proteolysis of sterol regulatory element binding protein-1 and activating transcription factor 6 in castration-resistant prostate cancer.
    Guan M; Fousek K; Chow WA
    FEBS J; 2012 Jul; 279(13):2399-411. PubMed ID: 22540830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KLF14 potentiates oxidative adaptation via modulating HO-1 signaling in castrate-resistant prostate cancer.
    Luo XH; Liu JZ; Wang B; Men QL; Ju YQ; Yin FY; Zheng C; Li W
    Endocr Relat Cancer; 2019 Jan; 26(1):181-195. PubMed ID: 30400002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of INPP4B gene transfection combined with PARP inhibitor on castration therapy-resistant prostate cancer cell line, PC3.
    Ding H; Sun Y; Hou Y; Li L
    Urol Oncol; 2014 Jul; 32(5):720-6. PubMed ID: 24837011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesenchymal stem cells recruited by castration-induced inflammation activation accelerate prostate cancer hormone resistance via chemokine ligand 5 secretion.
    Yu Y; Zhang Q; Ma C; Yang X; Lin R; Zhang H; Liu Y; Han Z; Cheng J
    Stem Cell Res Ther; 2018 Sep; 9(1):242. PubMed ID: 30257726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of erythropoietin and erythropoietin receptor in castration-resistant progression of prostate cancer.
    Ye C; Chen GH; Chen X; Qin SF; Shi MF; Zhou T
    Asian J Androl; 2020; 22(4):422-426. PubMed ID: 31417010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipocalin 2 over-expression facilitates progress of castration-resistant prostate cancer via improving androgen receptor transcriptional activity.
    Ding G; Wang J; Feng C; Jiang H; Xu J; Ding Q
    Oncotarget; 2016 Sep; 7(39):64309-64317. PubMed ID: 27602760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nucleoporin 62 and Ca(2+)/calmodulin dependent kinase kinase 2 regulate androgen receptor activity in castrate resistant prostate cancer cells.
    Karacosta LG; Kuroski LA; Hofmann WA; Azabdaftari G; Mastri M; Gocher AM; Dai S; Hoste AJ; Edelman AM
    Prostate; 2016 Feb; 76(3):294-306. PubMed ID: 26552607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of androgen receptors by NaAsO
    Kim Y; Park SE; Moon JW; Kim BM; Kim HG; Jeong IG; Yoo S; Ahn JB; You D; Pak JH; Kim S; Hwang JJ; Kim CS
    Prostate; 2017 Jul; 77(10):1128-1136. PubMed ID: 28556958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoblasts promote castration-resistant prostate cancer by altering intratumoral steroidogenesis.
    Hagberg Thulin M; Nilsson ME; Thulin P; Céraline J; Ohlsson C; Damber JE; Welén K
    Mol Cell Endocrinol; 2016 Feb; 422():182-191. PubMed ID: 26586211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of novel genes that regulate androgen receptor signaling and growth of androgen-deprived prostate cancer cells.
    Levina E; Ji H; Chen M; Baig M; Oliver D; Ohouo P; Lim CU; Schools G; Carmack S; Ding Y; Broude EV; Roninson IB; Buttyan R; Shtutman M
    Oncotarget; 2015 May; 6(15):13088-104. PubMed ID: 26036626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactive stroma component COL6A1 is upregulated in castration-resistant prostate cancer and promotes tumor growth.
    Zhu YP; Wan FN; Shen YJ; Wang HK; Zhang GM; Ye DW
    Oncotarget; 2015 Jun; 6(16):14488-96. PubMed ID: 25895032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antioxidant therapy alleviates oxidative stress by androgen deprivation and prevents conversion from androgen dependent to castration resistant prostate cancer.
    Shiota M; Song Y; Takeuchi A; Yokomizo A; Kashiwagi E; Kuroiwa K; Tatsugami K; Uchiumi T; Oda Y; Naito S
    J Urol; 2012 Feb; 187(2):707-14. PubMed ID: 22177207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.
    Komura K; Jeong SH; Hinohara K; Qu F; Wang X; Hiraki M; Azuma H; Lee GS; Kantoff PW; Sweeney CJ
    Proc Natl Acad Sci U S A; 2016 May; 113(22):6259-64. PubMed ID: 27185910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.